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ABSTRACT
Alajman, Amal Fahad. M.S., Microbiology and Immunology Graduate Program,
Wright State University, 2016. Comparing Antibody-Coated Immune Beads With
Flow Cytometry to Measure β-2-Microglubulin+ Murine Spleen Cells.

In diseases like AIDS, Multiple Myeloma, Multiple Sclerosis (MS), Type 1 Diabetes, and
Systemic Lupus Erythromatosus the detection of major histocompatibility complex type 1
molecules (MHC 1) can be a helpful component of disease diagnosis and prognosis.
Most somatic mammalian cells display to varying degrees major histocompatibility
complex (MHC) class 1 antigen on the cell surface. MHC1 molecules consist of a
polymorphic alpha α chain and a monomorphic beta chain, beta 2 microglubulin (β2m).
The β2M composition is fairly constant within a species whereas the alpha chain is not.
The polymorphic alpha chain is encoded by an MHC complex gene that is specific for
each member of the species. The consistency of the β2M protein within a species makes
it a superior target to the variable α chains when attempting to quantify MHC1 molecules.
Currently, there are no reagents available to identify the MHC1 antigen within an outbred
population such as human or laboratory animals other than defined in bred mouse strains.
In this study, the presence of MHC1 molecules on spleen cells from an outbred mouse
strain (ICR strain) was evaluated by looking for monomorphic β2m molecules. The two
methods, which were used to obtain the numbers of β2m+ mouse spleen cells, were flow
cytometry and the antibody-latex bead method. Similar numbers of β2m- positive cells
were obtained using these two methods (7-9%). These results demonstrate that the
antibody-coated beads are a suitable, less expensive and time saving alternative to
determine the numbers of β2m+ positive cells when compared to flow cytometry.
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HYPOTHESIS
The hypothesis of our study is that the using antibody coated latex beads will give
comparable results to those of flow cytometry in detecting cells bearing the light chain of
MHC I.
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Introduction
This study is a continuation of the work of Sana Alhawsawi who used
immunohistochemistry to detect the expression of the polymorphic alpha chain and β -2microglobulin (β2m) of the major histocompatibility complex I (MHCI) in different
mouse tissues (spleen, stomach, small and large intestine). She found no difference in
expression using antibodies specific for the alpha-chain verses the β -2-microglobulin.
The goal of the present study was to quantitate the expression of β -2-microglobulin on
mouse spleen cells using flow cytometry and direct counting of cells attached to
antibody-coated latex beads.

Flow cytometry detects single cells through laser detector beams. The procedure
of the flow cytometry starts by using fluorescent-labeled antibodies specific to cellsurface markers that are selected to show the cell population of interest (Jahan-Tigh,
Richard R., et al. 2012). This entire process lasts approximately 10 hours. The cost of
flow cytometry ranges from $30,000 to $150,000 (Matthews, 2006). Developed and
developing countries could both benefit from a faster and more affordable method to
detect cell populations of interest.
The beads method involves microscopically counting cells attached to latex
beads. In this study, latex spheres were coated with a β -2-microglubulin rabbit
polyclonal antibody and used to enumerate the numbers of single positive β -2microglubulin+ cells in a suspension of mouse spleen cells.
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Super Active Latex Beads
There are five types of Super active latex beads: carboxylate modified beads
(CML), chloromethyl beads, aldehyde/amidine beads, aldehyde/sulfate beads, and
aliphatic amine. The functional groups of super active latex beads have a very high
density for covalent coupling of proteins to the particles. The super active layer consists
of a three- dimensional layer that raises the colloid stability of the particles and makes it
easier for the protein to bind to the particles. This type of bead maintains the protein
structure more than the distortion of proteins caused by absorption onto a rigid surface
("Super Active Latex Beads," n.d.).
Carboxylate-modified beads are composed of latex polymer particles that have
highly charged and relatively hydrophilic surfaces with a pka of 5-9. These features
create a perfect site for covalent bond formation with the antiβ-2 macroglobulin rabbit
polyclonal antibody coating and present less distortion of the antibody structure ("Super
Active Latex Beads," n.d.).
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Literature Review

There are two major defensive systems against different kinds of pathogens:
Innate and adaptive immune systems (Abele and Tampe, 2004). Genes of the host germ
line encrypt the innate immune system while the genes of the host somatic line encrypt
the adaptive immune system (Abele and Tampe, 2004).
Two types of cells are responsible for antigen recognition in the adaptive immune
system: B and T cells. The B cells have evolved in humoral immune response. T cells
associate with major histocompatibility complex (MHC) molecules in recognition of
antigenic peptides (Abele and Tampe, 2004).
The major histocompatibility complex (MHC)
The major histocompatibility complex (MHC) is essential part of the immune
system in all vertebrates by presenting peptides to T cells. The MHC gene is divided to
two groups, MHC class I, and MHC class II. MHC molecules can mediate the interaction
of white blood cells (WBCs), which are also known as leukocytes with each other or with
other cells in the body. MHC genes specify the human leukocyte antigens (HLA)
(Hughes and Yeager, 1998).

The MHC class I
MHC class I molecules are located on every nucleated somatic cells (Reche and
Reinherz, 2003). MHC class 1 molecules present the antigens from cytosolic
(intracellular) proteins to T cells that express the CD8 cell-surface glycoprotein
(Bjorkman and Parham, 1990). Consequently, the process of MHC class I presentation is
called the cytosolic or endogenous pathway. Virus specific cytotoxic T lymphocytes
3

(CTL) bind to somatic cells that present MHC class I molecules on cell surface for
peptides that derived from viral antigens and eradicate infected cells (Hewitt, 2003).
MHC class I antigens contain two polypeptide chains, variable heavy (α chain)
and light chains (β2microglobulin). The α chain has three domains α1, α 2, and α 3. The
variable heavy chain (α chain) is polymorphic and encoded by human genes called HLAA, HLA-B, and HLA-C (Figure 1) (Bernal et al., 2012).
The two chains (α and β2-microglobulin) are bound together by a non-covalent
bond via the interaction between β2m and the α3 domain. The α3 domain binds to the
CD8 co-receptor on T cells. On the other hand, the α1-α2 heterodimer bind to T cell
receptor (TCR) on cytotoxic T cell (Bernal et al., 2012). Peptides that attached to MHC
class I glycoproteins are 8-10 amino acids long (Gil-Torregrosa et al., 1998).
The β2m chain is monomorphic and is encoded by the β2m gene. The
composition of β2m is constant in every cell of a given species. The β2m protein is small
enough to be filtered by the glomerular membrane and be completely reabsorbed by the
proximal tubule back into the blood. Hence, serum levels have a significant impact on
glomerular function in disease conditions. If glomerular function is damaged, serum
levels increase in reverse ratio to glomerular filtration rate (Karlsson et al., 1979). In
some diseases including Multiple Myeloma, Multiple Sclerosis (MS), AIDS, Type 1
Diabetes, and Systemic Lupus Erythromatosus the expression of the β2m chain in major
histocompatibility complex type 1 molecules (MHC 1) can be a useful factor in disease
diagnosis and prognosis (Fernando et al., 2008). The polyclonal antibody against β2m is
easy to use, inexpensive, and is readily accessible in non-specialized laboratories
(Delgado et al., 2009).
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The MHC class II
MHC class II molecules are usually found on antigen presenting cells such as
dendritic cells, macrophages, mononuclear phagocytes, and some endothelial cells, and B
cells (Reche and Reinherz, 2003). MHC II molecules present antigens that derive from
extracellular proteins to T cells expressing the CD4 cell-surface glycoprotein (Bjorkman
and Parham, 1990). The pathway of MHC class II of antigen presentation is called the
endocytic or exogenous pathway.
MHC class II molecules are similar to MHC class I molecules, in that they are
also heterodimers, but MHC class II molecules consist of two polymorphic peptides
chains (α and β chains). Both of these chains consist of two domains, α1, α2, β1, and β2
that are encoded within the HLA gene (Figure 1). Since the antigen -binding groove of
MHC class II glycoproteins is open at both ends, it binds to peptides between 15 and 24
amino acids in length. In contrast, the antigen binding groove on class I molecules is
closed at each end and binds smaller peptides (8-12 amino acids) (Ting and Trowsdale,
2002).
The expression of MHC class II is stimulated by INF-γ at the transcriptional level
(Ting and Trowsdale, 2002). The expression of MHC-II glycoprotein is activated via the
initiation of the protein tyrosine kinases JAKI and JAK2 signaling cascade, leading to
tyrosine phosphorylation, and STAT1 dimerization. Subsequently, STAT1 dimers are
transported to the nucleus where they attached to IFN-γ-activated sequence (GAS)
elements in the promoters of IFN-γ genes (Giroux et al., 2003).
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INF- γ is a cytokine that plays a critical role in the innate and adaptive immunity
against viral, bacterial and protozoa infectious agents. In the immune system, IFN-γ
directly prevents viral replication. IFN-γ also regulates antigen presentation, proliferation,
and differentiation of lymphocytes. Furthermore, high levels of IFN-γ serve as an
indicator of T helper 1 (Th1) activity in stimulating the phagocytic actions of
macrophages (Billiau et al., 1998). Natural killer cells (NK) and natural killer T (NKT)
cells produce INF- γ as part of the innate immune response, while the CD4 Th1 and CD8
cytotoxic T lymphocyte (CTL) as part of adaptive immunity (Ting and Trowsdale, 2002).
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Figure 1. Schematic diagram that shows the differences in the structure of two classes
of major histocompatibility complexes (MHC). MHC class1 contains three α-domains
and oneβ-2microglubulin molecule. The peptide-binding groove is found between α1 and
α2 domains. MHC class II has two α-domains and two β-domains. The peptide-binding
groove is found between α1 and β1 domains (Modified from Zhong et al., 2011).
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MHC class I pathway for antigen presentation
The peptides binding to the MHC class I are generated by the 20 S proteasome
(Lehner et al., 1998) and the assembly of MHC class I molecules occurs in the
endoplasmic reticulum (ER) lumen by the formation of β-2-microglubulin dimers
(Figure. 2) (Ortmann et al., 1997) Two subunits LMP2 and LMP7 are essential for
degradation of cytosolic proteins to small peptides (Lee et al., 1999). The transporter
associated with antigen processing (TAP) facilitates the translocation of the peptides
from the cytosol into the ER lumen (Neumann and Tampe, 1999).

Two stages are involved in the formation of MHC1 glycoprotein in endoplasmic
reticulum (ER) in: the early phase and the later phase. The folding of the alpha chain α
with the β2m chain occurs in the early stage. The late phase involves the formation of the
‘peptide-loading

complex’

(PLC).

In

the

early

stage,

monoglycosylated

(Man9GlcNAc2Glc1), which is sugar that chemically associated at position 86 of α chain
with conserved asparagine. This facilitates the binding between the trans-membrane
domain of α chains in MHC class 1 and chaperone calnexin (Antoniou and Powis, 2008).
The structural domain of calnexin (glycan protein) promote the binding of MHC class 1-α
chains with the extended proline-rich domain and helps the formation of a ‘folding cage’
for the early phases of assembly. However, the proline-rich domain recruits oxidoreductase ERp57, which is one member of the protein disulphide isomerase family that
can decrease, oxidize or isomerize disulphide bonds. In the late stage, MHC class I α
chains binds to the immunoglobulin-binding protein (BiP). BiP binds temporarily, or for
a long period either to newly synthesized or misfolded proteins in the MHC I α chains
(Antoniou and Powis, 2008). After that, the calnexin is transported by another soluble ER
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lectin, calreticulin, which involves prolonged proline- rich domain that recruits ERp57
(Antoniou and Powis, 2008). The calreticulin binds to TAP to form the peptide loading
complex (PLC) with the help of Tapasin (TPN), which is an accessory molecule of MHC
I. PLC is very critical to assisting appropriate MHC I loading before the entire complex is
transfered to the cell surface. The peptide-loading complex (PLC) coordinates peptide
transport and recognition in addition to the efficient loading of high-affinity peptides onto
MHC I glycoproteins (Blees et al., 2015). When MHC class I molecules dissociate from
TAP, they are transferred to the cell surface by cargo vesicles for transfer to the Golgi.
Then, MHC I molecules display their antigen cargo to Cytotoxic T lymphocytes CTLs
(Figure 2) (Hewitt, 2003).
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Figure 2.The MHC class I antigen presentation pathway.
First, proteasome generate the proteins in the cytosol. Then, peptides translocate into the
ER lumen by TAP. ER chaperones calnexin, calreticulum and ERP57 facilitates the
MHC class I molecules folding and assembly in the ER. When Peptides bind to MHC
class I molecules, it dissociates from TAP and then is transported to the plasma
membrane (Modified from Hewitt, 2003).
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MHC class I on Human and Mouse
In humans, the α chains of MHCI are different than that found in mice. The α
gene of MHCI is known as human leukocyte antigen (HLA) and displays three-class
loci (A, B and C) known as HLA-A, HLA-B, and HLA-C (Pick et al., 2012). While in
mice, the MHC I α chain is coded by the H-2 gene. The MHC I H-2 gene presents three
loci (K, D, and L). In each locus, both alleles are expressed, so these genes are extremely
polymorphic. For example, HLA-B gene has about 500 known alternative genes, over
200 variants of HLA-A genes, and about 100 variants of HLA-C genes (York and Rock,
1996). In humans, the major histocompatibility complex class I is found on the
chromosome 6 while in mice it is located on the chromosome 17 (Relle and Schwarting,
2012). In humans, β2m is found on chromosome 15 while in mice is located on
chromosome 2. One allele is found in humans, whereas seven alleles are found in mice
(York and Rock, 1996).

Biological roles of MHC I
Beside the well-known role of human MHC I glycoprotein in the immune
response, some studies have indicated that human MHC I plays a role in some
autoimmune and inflammatory diseases. MHC I seems to be important in the
pathogenesis of multiple sclerosis (MS), Crohn’s disease (CD), type 1 diabetes (T1D),
ulcerative colitis (UC), systemic lupus erythematosus (SLE), and rheumatoid arthritis
(RA) (Fernando et al., 2008). MS affects the central nervous system and is a chronic
inflammatory syndrome and T1D is a chronic autoimmune disease described by T cellmediated impairment of pancreatic cells, which results in insulin insufficiency. SLE, also
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known as lupus, is an autoimmune disease that can affect multiple organ systems. Lupus
is a genetic disease linked to the genes of the major histocompatibility complex
(MHC)(Relle and Schwarting, 2012). CD and UC are inflammatory bowel diseases of the
gastrointestinal tract. Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis
which often will have systemic symptoms (Fernando et al., 2008). In inflammatory bowel
disease (IBD) patients, the activity of β2m may enhance the activation of macrophages
and T-lymphocytes (Yılmaz et al., 2014). In autoimmune diseases, the immune response
of the body is abnormal in that it attacks antigens and tissues that are normally present in
the body (Relle and Schwarting, 2012). The role of human MHC I in autoimmune
diseases is not well understood, but the main cause for autoimmune diseases could be due
to the disequilibrium alleles at multiple loci in the human MHC I (Fernando et al., 2008).
MHC I has an important role in transplantation complications, including graft
rejection in human liver. In healthy liver tissue of humans, the expression of both chains
of MHC 1 is very low (Steinhoff, 1990). In a liver transplant, the recipient’s immune
system targets the donor cells causing graft rejection. During rejection and after liver
transplantation, the level of human MHC I protein is increased notably in the plasma
membrane of the hepatocytes, epithelia, endothelia, and Kupffer cells (Steinhoff et al.,
1990). The MHC I molecule has to be compatible in both donor and recipient cells in
order for grafts to be accepted (Carcia et al., 2012).

In brain development, the function of MHC class I in human is similar to its
function in mice. The genes of both MHC class I and β2m are expressed in humans and
mice during cerebellar cortex development (Lv et al., 2014). The expression of H2Kb/Db and HLA-B/C molecules increase during the growth of the brain in mice and
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humans, respectively, but they both decrease after birth (Lv et al., 2014). These findings
emphasize the role of MHC class I in plasticity and synaptic remodeling during cerebellar
development.

Recently it has been discovered that MHC I is expressed on neurons (Cebrián et
al., 2016). There is evidence that expression of MHC I is necessary for the development
of the brain structure involved in memory (Cebrián et al., 2016). Furthermore, an
overexpression of neuronal MHC I also appear to play a role in neurodegenerative
disorders like Parkinson’s disease (PD) (More et al., 2013).
β2-microglobulin
All nucleated cells synthesize β2microglobulin polypeptide and it is found in most
cells. It forms the light chain of MHC class I (Chelazzi and Senaldi, 1986). It has a low
molecular weight 11,800 kDa and has structure that is similar to the constant region of
immunoglobulin molecules (IgG). This protein can be isolated from human urine
(Manicourt et al., 1978). β2m is not significantly polymorphic and is similar in all
mammals (York and Rock, 1996). β2m is a non-glycosylated protein and consists of 100
amino acids. The level of normal serum β2m is usually less than 3mg/L, but in elderly
people it gradually increases. Kidneys play an important role in β2m catabolism as
evidence by the high serum levels of β2m in the renal failure patients (Chelazzi and
Senaldi, 1986). High serum levels of β2m are present in neoplastic and non- neoplastic
diseases, and acquired immunodeficiency syndrome (AIDS). Also, β2m is useful marker
in the evaluation of the multiple myeloma (Chelazzi and Senaldi, 1986). Many studies
show that the level of serum β2m may be elevated abnormally in patients with different
types of malignant tumors, as compared to controls (Forman, 1982).
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Serum β2 microglobulin and diagnosis of human disease
Serum β2 microglubulin has been determined as an important prognostic marker
in several diseases such as hematologic malignancies and non-hematologic disorders
(Yang et al., 2006) .The levels of β2 microglubulin were elevated in lymphoma
proliferative disorders including multiple myeloma, and chronic lymphocytic leukemia
(Henne et al., 1996). In 1982, Bataille et al found that the levels of serum β2m were
significantly elevated in patients with multiple myeloma at time of diagnosis comparable
to normal individuals (bataille et al., 1982). Also, the levels of serum β2m in multiple
myeloma seem to correlate well with survival time. Patients with the highest level of
serum β2m have the shortest survival (Bataille, and Grenier, 1987). In addition, there is a
correlation between the levels of serum β2m and the stage of the multiple myeloma
disease. In the late stage of the disease, patients have higher levels of β2m than in the
early stage of the disease (Chelazzi and Senaldi, 1986). The elevation of serum β2m in
multiple myeloma indicates it functions to increase inflammation (Prizment et al., 2014).

In the immune system, the propagation of B cells and the production of antibodies
are tightly regulated. In multiple myeloma, usually the chromosomal translocation occurs
between the immunoglobulin heavy chain gene (on chromosome 14, locus q32) and an
oncogene (often 11q13, 4p16.3, 6p21, 16q23 and 20q11). This results in dysregulation of
the oncogene, which is the initiating consequence in the pathogenesis of myeloma. (Kyle
and Rajkumar, 2004). In addition, the serum of patients with renal failure will have high
levels of β2 microglubulin. In patients with healthy kidneys, the normal serum levels of
β2 microglubulin are 1.5 to 3-mg/L while in renal failure, the levels increase by 60-fold
14

and more (Winchester et al., 2003).
The levels of serum β2 microglubulin are elevated in human Immunodeficiency
virus (HIV) infection, acquired immune deficiency syndrome (AIDS), and autoimmune
disorders such as rheumatoid arthritis. However, the high level of β2 microglubulin can
activate or inhibit the immune system. For example, in HIV patients, the high level of
serum β2 microglubulin is associated with progression to AIDS while the levels of serum
β2 microglubulin correlates with poor prognosis in the hematologic malignancies (Xie et
al., 2003).
Disease conditions associated with elevated levels of serum β2 microglubulin
include multiple sclerosis, meningeal dissemination, and sarcoidosis (Adachi, 1991).
Increase the serum levels of β2m are due to that the β2 microglubulin is shed from the
surface of nucleated cells into serum during these diseases. These syndromes are
involved with activation of the immune system and/or increased cell turnover (Gooptu et
al., 2014).
Staging of multiple myeloma
Multiple myeloma is a malignancy of B- lymphocytes. These malignant
lymphocytes express more β2m (Kumar et al., 2008). International myeloma working
group (IMWG) has described a staging system of multiple myeloma known as
international staging system (ISS) based on two factors: β2m, and serum albumin (Raja,
2012). The level of serum β2m is normally less than 2mg/L (Xie et al., 2003), but in
multiple myeloma it increases up to 5.5 mg/L (Raja, 2012). International staging system
(ISS) has been described three stages of Multiple Myeloma (Raja, 2012). In stage I, the
level of Serum β2 microglobulin is <3.5-mg/L and albumin ≥3.5 g/DL and the survival
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duration is an average of 62 months. In stage II, the survival duration is 44 months and
the β2 microglobulin is ≥5.5 mg/L and the patients survive up to 29 months (Raja, 2012).
The high levels of serum β2m in multiple myeloma are associated with increased cell
proliferation (Karlsson et al., 1979).

β2-microglobulin as a negative regulator of the immune system
Dendritic cells (DCs) are key cellular immune elements in peripheral tissues.
When DCs encounter pathogens, they are activated and travel to the secondary lymphoid
organs, where they stimulate a specific T-cell response (Xie et al., 2003). DCs are the
most effective antigen presenting cells (APCs) and can stimulate different cells including,
naïve CD4+ and CD8+ T cells and B cells. DCs can initiate both the primary and the
secondary immune response. DCs are the key targets for some conditions that involve an
alteration T cells activity, such as transplantation, autoimmune disease, some cancers,
and immunodeficiency. However, high levels of β2-microglobulin have a negative impact
on the immune system. Cells that are treated with β2-microglobulin had decreased
antigen presentation capability and enhance tumor growth and survival by producing
cytokines, such as IL-6, IL8, and IL-10. These cytokines induced the secretion of weaker
IL-2 and INF-ϒ that activate T-cell responses, and compromised DC ability to mount a
type I T-cell response. β2-microglobulin treated cells inhibit the Raf/MEK/ERK signal
transduction cascade and activate STAT3, a protein that has a crucial role in cell growth,
proliferation, and survival (Xie et al., 2003).
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Materials and Methods
Animal model.
Spleens were harvested from three month old ICR female and male mice by Dr.
Emily Dudly and placed in Dulbecco’s Modified Eagle’s Medium (DMEM) (HyClone,
Fisher Scientific, Pittsburgh,Pa). The spleen was macerated between the frosted ends of
two suspended microscope slides. The spleen cells were in 5 ml 1X PBS and centrifuged
for 5 min at 1500rpm. To sediment the cells, the cells were re-suspended in 5ml 1x PBS
and quantified using both the beads method and flow cytometry.
The use of antibody-coated beads to detect β2microglubulin on cells
By using these antibody-coated beads, the cell suspension or the β2m marker can
be counted under light microscopy. The beads method requires three reagents: labeling,
blocking, and staining reagents. The labeling reagent, the antiβ-2 macroglobulin rabbit
polyclonal antibody (Santa Cruz Biotechnology, INC) was coated on 1.4 μm carboxylate
modified super active latex beads (Life Technologies, Grand Island, NY). 20% normal
rabbit serum (Sigma-Aldrich, St.Louis, MO) is used as blocking agent (with 3% BSA and
5% tween). The blocking reagent limits the non -specific binding. The staining reagent
can lyse red blood cells and contains 0.025% crystal violet stain and 2% acetic acid in
distilled water.
The passive adsorption method was used on the labeling reagent to coat the beads.
Attachment of antibodies to carboxylate modified super active latex beads occurred by
physical adsorption. The MES buffer (Fisher Scientific, Pittsburg, PA) (0,025M,PH6,
wash buffer (phosphate buffered saline, 0.1M, PH 7.2), and storage buffer (phosphate
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buffered saline, 0.1M, PH 7,2, 0.1 glycine, 0,1% NaN3) were used. The high value of the
pH of MES buffer is identical to the isoelectric point of the β-2 microgubulin. Therefore,
it will increase the protein density on the particle surface (“Passive Adsorption Protocol,”
n.d.).
MES buffer Preparation (2- N-Morpholino-EthanesulfonicAcid)
48.8 mg of MES was weighted and added to 5 ml of double distilled water. Then,
1 N NaOH was added in order to increase the PH value (Appendix 1).
Storage Buffer preparation
100 mg glycine was mixed with 100 mg sodium azide, then the volume was
brought to 10 ml PBS (Appendix 1).
The quantities of Antibody and super latex beads
The following equation determines the amount of antibody required for coating
beads:
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 =

𝑤𝑒𝑖𝑔ℎ𝑡 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑖𝑛 𝜇𝑚

(Appendix 1).
The preparation of the super latex beads labeling with antibody
We diluted 2.5 ml latex beads in 10 ml MES buffer. Then, we centrifuged the
compound for 20 min to 3000rpm. Then, re-suspends the pellet in 10 ml MES buffer.
And we centrifuged it again at same condition. We re-suspended the pellet in 5 ml MES
buffer. After that, we added the calculation amount of the antibody and Incubated the
mixture at room temperature overnight. Then, we centrifuged the latex/ antibody mixture
and re-suspended the pellet in 10 ml phosphate buffer saline (PBS). We centrifuged the
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pellet 3 times for 20 min at 3000 rpm and Re- suspended the final latex of β2m in 5 ml
storage buffer. The latex was stored at 4 °C ("Passive adsorption protocol"n.d.)
(Appendix 2).

Counting β2microglubulin by beads method
For each sample we used two 12 ×75 mm tubes: test tube# 1; label with B+L and
test tube#2; label with S. We pipetted 100 μl of agent S into the test tube that labeled with
S. (Figure 3.A). Then, we put 100 μl of spleen cells suspension into the test tube labeled
with B+L. (Figure 3.B). We added 10 μl of the blocking agent (B) to the spleen cells
suspension in the tube labeled with B+L. (Figure 3.C). Then, we added 10 μl of the
Labeling agent (L) to the B+L test tube. (Figure 3.D). We added 10μl from the mixture in
the B+L test tube to the S tube. (Figure .3.E). By using the hemocytometer (Figure. 3.F).
Under the light microscope, cells that had three or more latex spheres attached were
counted as having β2m ("Manual CD4 count kit” n.d.) (Appendix 3).
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Figure 3.The steps of the bead method. (A-F). Figures demonstrate the steps of the
bead method. The letter B + L represents blocking reagent + labeling reagent and the S
letter represents staining reagent. Adapted from ("Manual CD4 count kit" n.d.).
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Figure 4.The attachment of three or more beads to cells. Images under light
microscopy demonstrate the attachment of three or more beads to β2m+ cells.
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Figure 5.No attached beads.
Images under microscope show no beads attached to the β2m+ cells.

22

Absolute Count
The cells that have no attached beads (figure 3), one bead attached, or two beads
attached were excluded from count. One or two attachments of the latex beads to the
antibody can be by chance and it is non-specific. Three attachments of the latex beads to
the β2m antibody are more definitive and indicate the binding is not accidental. The
results of the control experiment indicated that cells never exceeded two beads. The next
formula demonstrates the absolute counting for β2m+ cells in mice spleen:
𝛽2𝑚+ 𝑐𝑒𝑙𝑙𝑠 ∕ 𝔲𝑙 =
𝛽2𝑚+ 𝑐𝑒𝑙𝑙𝑠 𝑛𝑢𝑚𝑏𝑒𝑟𝑠 × 𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑑𝑒𝑝𝑡ℎ 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎(𝑚𝑚2 )
(Appendix 4).
Counting β-2microglubulin by Flow Cytometry
Flow cytometry uses laser beams to analyze the chemicals and physical
proprieties of any particles in a fluid. It is commonly used for cell counting, sorting, and
biomarker detection. The process and reagents for surface markers can be very costly. In
this study, the flow cytometry were used to count the number of β2m+ cells. The indirect
antibody was used. For the isotype control, normal rabbit serum (Sigma Aldrich,
St.Louis, MO) was used. The primary antibody used was the anti-β2m rabbit polyclonal
antibody (Santa Cruz Biotechnology, Dallas, Texas) and the secondary antibody was goat
anti- rabbit IgG (FITC)(Santa Cruz Biotechnology, Dallas, Texas). The purpose of the
isotype control was to measure the level of non-specific background signal caused by
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primary antibodies. This control was used to distinguish non-specific background
signals from specific antibody signals.

The spleen cells suspension was washed three times with 1% BSA (bovine serum
albumin) and centrifuged at a speed of 1200 rpm for 5 minutes. After that, 3%BSA was
used for 30 minutes for the purpose of blocking non-specific staining and was incubated
at room temperature. Then, the cells were washed again three times with 1% BSA and
centrifuged at a speed of 1200 rpm for 5 minutes. The fluorochrome conjugated primary
antibody specific for β2m was added and incubated with the cells for 15 to 45 min 4°C in
the dark 5 μg antibody / ml with 100 μl of 3% BSA for each sample. Then, cells were
washed three times with 1% BSA and centrifuged at a speed of 1200 rpm for 5 minutes.
The secondary conjugated antibody was added and incubated with the cells for 15 to 45
min 4°C in the dark (Add 0.1 to 10 μg antibody/ml then diluted with 100 ml of 3% BSA).
Then, the cells were washed and centrifuged again with 1% BSA 3X (1200rpm, 5min).
Re-suspend the cells on cold PBS, 10% FCS, and 1% sodium azide until analysis within
24 hours. The results from flow cytometry were analyzed using the FCS Express program
(Figure 6).
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Figure 6: Flow Cytometry Analysis of β2-microglubulin polyclonal Antibody (A-E).
It shows the analysis of flow cytometer of ICR female mouse spleen cells suspension
using β2-microglubulin polyclonal antibody at 20,000 events. The number of
β2microglubulin+ cells per sample = 20,000/ volume at which 20,000 was detected
(Dataanalysis in Table 1-3).
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Results
The number of β2m+ cells was enumerated by using two different methods; flow
cytometry and bead method in spleen cells from two three-months-old ICR females and
three three-month-old ICR males. The overall number of cells in all spleens of ICR
female and male mice was around 10 million. The results of both methods flow
cytometry and bead methods are similar and no significant differences between them. It is
important to note that the bead method results were higher than flow cytometry in terms
of β2m+ cell counts. The results were analyzed by using Sigma Plot. The numbers of
β2m+ cells were between 400-500 cells/ μΙ.
Table 1 demonstrates the total numbers of β2m+ spleen cells individual samples
from five ICR female and male mice by using flow cytometry and bead method. Oneway ANOVA shows that the differences in the mean values between the two methods are
not great enough and there is not a statistically significant difference (P = 0.058) (Mean
of the flow cytometry β2m+ = 375 ± 25, and mean of the bead method β2m+ = 466 ± 32,
mean ± SEM). Table 2 indicates the total number of β2m+ spleen cells per sample. The
absolute number of spleen cells was approximately 10 million in all samples.
In addition, the percentage of the total numbers of single β2m+ cells to the total
number of spleen cells is presented in Table 3. There were no significant differences
between the two methods. The percentage of total β2m+ cells to the total spleen cells
counts was between 7 and 9%.
We excluded ICR M 2 sample from tables 4, 5, and 6 from our data due to the
statically insignificant curve of the isotype control.
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Table 1
Comparison of β2m+ cell numbers determined by flow cytometry and immunobeads.
Mouse

Flow cytometry

Bead method

ICR F 1

313/μΙ

467/ μΙ

ICR F 2

340/μΙ

394/ μΙ

ICR M 1

373/μl

408/μl

ICR M 2

392/μl

576/μl

ICR M 3

461/μl

489/μl

Mean ± SEM

375 ± 25/μl

466 ± 32/ μl

In Table 1, β2-microglubulin+ spleen cell counts from female and male ICR mice
were determined using flow cytometry and the immune bead method. Note that the
numbers are not significantly different from one another when pairwise comparisons
were made using one-way ANOVA.

27

Table 2
Numbers of Single β2-micoglubulin+ Cells Per Sample.
Mouse

Flow cytometry

Bead Method

ICR F 1

626,000

934,000

ICR F 2

680,000

788,000

ICR M 1

746,000

816,000

ICR M 2

784,000

1,152000

ICR M 3

922,000

978,000

Mean ± SEM

751,600±505,07

933,600±650,76

In Table 2, the results are shown for total β2-micoglubulin+ cells in each sample
as determined by flow cytometry and immune bead. These results were not significantly
different between the two methods. (One-way ANOVA pairwise comparisons).
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Table 3
Percentage of Single β2microglubulin+ Cells / Total Spleen as determined by flow
cytometry and immunobead counting.
Mouse

Flow cytometry

Bead Method

ICR F 1

6

9

ICR F 2

6

7

ICR M 1

7

8

ICR M 2

7

11

ICR M 3

9

9

Mean ± SEM

7± 0,5

8± 0,6

In Table 3, no significant difference can be seen in the percentage of β2
microglubulin+ Cells / Total Spleen cells was found (One-way ANOVA, pairwise
comparisons).
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Table 4
Modified comparison of β2m+ cell numbers determined by flow cytometry and
immunobeads
Mouse

Flow cytometry

Beads

ICR F1

313

467

ICR F2

340

394

ICR M 1

373

408

ICR M 3

461

489

Mean± SEM

371±32

439±22

In Table 4, β2-microglubulin+ spleen cell counts from female and male ICR mice
were determined using flow cytometry and the immune bead method. Note that the
numbers are not significantly different from one another when pairwise comparisons
were made using one-way ANOVA.
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Table 5
Modified numbers of β2-micoglubulin+ Cells per Sample.
Mouse

Flow cytometry

Beads

ICR F1

626,000

934,000

ICR F2

680,000

788,000

ICR M1

746,000

816,000

ICR M3

922,000

978,000

Mean± SEM

743,500± 643,60

879,000±457,12

In Table 5, the results are shown for total β2-micoglubulin+ cells in each sample
as determined by flow cytometry and immune bead. These results were not significantly
different between the two methods. (One-way ANOVA pairwise comparisons).
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Table 6
Modified percentage of β2microglubulin+ Cells / Total Spleen as determined by flow
cytometry and immunobead counting.
Mouse

Flow cytometry

Beads

ICR F1

6

9

ICR F2

6

7

ICR M1

7

8

ICR M3

9

9

Mean± SEM

7±0,7

8±0,4

In Table 6, no significant difference can be seen in the percentage of β2
microglubulin+ Cells / Total Spleen was found (One-way ANOVA, pairwise
comparisons).
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Discussion
In this study, we evaluated the expression level of MHC I in murine spleen cells.
Since the MHC I α chain is encoded by variant HLA-A gene, and the β chain (β2microglobulin) is consistent (Bernal et al., 2012), the main purpose of the study was to
detect the MHC I molecules in mouse spleen cell using an antibody against the β2m
protein. The aim of the current study was to quantitate the expression of β2m on mouse
spleen cells using flow cytometry and direct counting of antibody-coated latex beads for
comparison with the results of Sana Alhawsawi who found no difference in expression of
spleen cells from C47BL/6 mice staining positive for the alpha-chain of MHCI compared
to the β2m (S. Alhawsawi, MS Thesis, Wright State University, 2015). In the present
study, the numbers of β2m+ cells in mouse spleen suspensions from outbred ICR Swiss
mice were also similar using flow cytometry (typical method) and counting antibodycoated latex beads. In this study, 7-9% of the spleen cells tested positive for β2m-labled
cells.

This number is low because these cells are obtained from healthy mice. In

Alhawsawi’s study, she found approximately 10% or less normal mouse spleen cells
staining for β2m. However, in spleens of mice that were infected with mouse parvovirus
class I, 80% or greater of the spleen cells stained positive for the β2m chain and for the
polymorphic alpha chain of C57Bl/6 mice.
Flow cytometry detects biomarkers, counts and sorts cells by using laser beam
and fluidics. The flow cytometry technique is more expensive than the bead method.
Flow cytometry also demands a highly trained person. The reagents of flow cytometry
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are costly from $30,000 to $150,000 ("Flow cytometry," n.d.). Furthermore, the process
takes approximately 10 hours. These factors indicate that we need an alternative method
to enumerate the β2m+ cells that is cheaper, easier to use, faster, and more accessible. In
contrast, the reagents of the bead method are not costly when compared to the cost of
flow cytometry. In the bead method, monoclonal antibody-coated- latex beads associate
with the surface of the cells that express β2m. When anti-β2m coated -latex beads bind to
the cell that displays β2m cell surface antigen, this binding forms a cell-latex bead rosette
that is easily recognized using light microscopy.
In this study, no statistically significant differences were seen using the bead and
flow cytometry method for enumerating single β2m+ cells. However, there was a little
difference in the absolute numbers of β2m+ cells in both methods. The results will be
more precise when using negative isotype control for beads method. In addition, the
numbers of β2m+ cells in beads method were higher compared to the flow cytometry due
to the sequence of the experiments. The results of this study suggest that the bead method
can be an alternative method to flow cytometry in identifying cell surface antigens.
These results support those of Allabidi (2014) in which the number of CD4+ and
CD8+ T lymphocytes in ICR Swiss mouse spleens yielded similar results using both
methods. In addition, the present study supports the observations of Othman (2015) in
which he found similar numbers of single mouse spleen cells displaying two surface
markers (CD5+ and CD19+) using flow cytometry and antibody-coated latex beads.
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Future studies
The bead method could be used to diagnose and monitor the progress of treatment
of metastatic embryonal carcinomas. Several studies have shown that in embryonal
carcinomas the expression of CD30 is elevated at both protein and mRNA levels. After
chemotherapy treatment, CD30 + cells are eliminated due to chemotherapy (Berney et al.,
2001). This demonstrates that CD30 could be a factor for stem cell regulation in early
embryonic development.
Multiple myeloma is a neoplastic disease of the plasma cells in which the plasma
cells (PC) proliferate abnormally in the bone marrow (Kumar et al., 2008). One
characteristic of multiple myeloma is osteolytic bone destruction. Since the levels of β2m
are highly expressed in patients with multiple myeloma (Raja, 2012), we can detect the
MHC class I expression by examining the number of β2m+ cells to monitor the disease
progression. Future studies can be done, by using western blot. Western plot will detect
the expression of specific intracellular proteins in samples while flow cytometry can be
used to detect the surface marker in suspended cells.
Immunohistochemistry (IHC) is a technique that can detect proteins in tissue by
antibody-antigen binding (Ramos-Vara and Miller, 2014). Since the levels of serum β2m
are highly expressed in inflammatory bowl diseases such as ulcerative colitis (UC),
Crohn’s diseases (CD), and rheumatoid arthritis (RA) (Fernando et al., 2008), we can
detect the expression of antiβ-2 macroglobulin rabbit polyclonal antibody by using
indirect immunohistochemistry to determine patient’s prognosis. In cases such as
metastases or carcinoma of unknown origin, immunohistochemistry can be helpful for
35

cell identification. IHC such as that described in this paper can also help distinguish
between benign and malignant tumors.
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Appendix
Appendix 1
MES buffer Preparation (2- N-Morpholino-EthanesulfonicAcid)
We weighted 48,8 mg of MES and added it to 5 ml of double distilled water. Then, we
tittered the PH value by using electrode with 1 N NaOH in order to increase the PH from 4 to 6.
After that, we transferred the MES buffer to the volumetric flask and diluted it to the final
volume of 10 ml of PBS (“Passive Adsorption Protocol,” n.d.).
Storage Buffer preparation
We weighted 100mg glycine, 100mg sodium azide. Then we mixed them and bring the
volume to 10 ml with PBS. We used glycine in order to fill any reactive site on the surface that
does not cover by protein. Bovine serum albumin (BSA) can be used to decrease non-specific
binding. On the other hand, the NaN3 is worked as biocide ("Passive adsorption protocol," n.d.).
The quantities of Antibody and super latex beads
The following equation determines the amount of antibody required for coating beads:
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For example, in this study, we coated 100 mg of 1.4 μm latex beads with 2 mg of β2m antibody,
so the weight of β2m = 2mg⁄1.4 μm = 1.4 mg of β2m antibody is needed to coat 100 mg of the
super latex beads ("Passive adsorption protocol” n.d.).
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Appendix 2
The preparation of the super latex beads labeling with antibody
1. 2.5 ml latex beads were diluted in 10 ml MES buffer.
2. Centrifuge the compound for 20 min to 3000rpm.
3. Remove the supernatant and re- suspend the pellet in 10 ml MES buffer.
4. Centrifuge again and remove the supernatant.
5. Re-suspend the pellet in 5 ml MES buffer. (The latex suspension is probably ~
20mg/ml).
6. Add the calculation amount of the antibody.
7. Incubate the mixture at room temperature overnight.
8. Centrifuge the latex/ antibody mixture.
9. Re-suspend the pellet in 10 ml phosphate buffer saline, PH=6.
10. Centrifuge the pellet 3 times for 20 min at 3000 rpm.
11. Re- suspends the final latex of β2m in 5 ml storage buffer (the concentration at 2%
solids).
12. Store the latex at 4 °C ("Passive adsorption protocol"n.d.).
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Appendix 3
Counting β2 microglubulin by beads method
1. Two 12 ×75 mm tubes were used for each sample.
a. Test tube# 1; label with B+L.
b. Test tube#2; label with S. (as in Fig3.A)
2. Pipette 100 μl of agent S into the test tube that labeled with S. (Fig3.B).
3. Put 100 μl of spleen cells suspension into the test tube labeled with B+L. (Fig3.C).
4. Add 10 μl of the blocking agent (B) to the spleen cells suspension in the tube labeled
with B+L. (Fig3.D)
5. Immediately, after adding the B agent, gently mix the B+L test tube for 2 min.
6. Add 10 μl of the Labeling agent (L) to the B+L test tube. (Fig3.E).
7. After adding the L agent, mix the B+L test tube for 2 min.
8. Place 10μl from the mixture in the B+L test tube into the S tube. (Fig.3.F).
9. Mix the test tube gently by hand for 15 sec.
10. Put the sample from step 9 on both chambers of the 0,1 mm deep hemacytometer.
11. By using the light microscope, cells that had three or more latex spheres attached to the
cells were counting as β2m ("Manual CD4 count kit” n.d.).
12. Under the light microscope, we count the cells that had three or more large latex spheres
attached as β2m+ cells.
XLVII

Appendix 4
Absolute Count
The cells that have no attached beads (figure 3), one bead attached, or two beads attached
were excluded from count. One or two attachments of the latex beads to the antibody can be by
chance and it is non-specific. While, three attachments of the latex beads to the β2m antibody are
more specific and it is not by chance.
The next formula demonstrates the absolute counting for β2m+ cells in mice spleen:
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Correction for sample Dilution=
A) 100 μl whole sample
+10 μl reagent L
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for two sides of 0.1 mm deep chamber ("Manual CD4 count kit," n.d.)

For example, if the count β2+ cells in both sides of 0.1 mm chamber were 50 the β2m+ cells count
can be calculated by applying the next formula:
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